title: Renal 20-hydroxyeicosatetraenoic acid synthesis during pregnancy.
abstract: We examined whether renal 20-hydroxyeicosatetraenoic acid (20-HETE) synthesis is altered during gestation. Renal microsomal arachidonic acid omega-hydroxylase activity increased by 50 and 48% in rats on days 12 and 19 of gestation, respectively. Renal microvessel 20-HETE synthesis increased by 50 and 82% in rats on days 6 and 12 of gestation, respectively, and returned to control levels at day 19 of gestation. In contrast, 20-HETE synthesis in isolated medullary thick ascending limb was unchanged from control levels on days 6 and 12 of gestation, but it increased twofold on day 19 of gestation. This increase on day 19 of gestation was associated with a twofold increase in urinary 20-HETE excretion, and it coincided with a 23-mmHg fall in blood pressure. Moreover, change in the rate of 20-HETE synthesis in microvessels was consistent with the level of expression of cytochrome P450 (CYP)4A proteins. Administration of the CYP4A inhibitor 1-aminobenzotriazole (ABT) for 2 days on day 12 of pregnancy or for 5 days starting on day 15 of pregnancy caused a transient but significant reduction in systolic blood pressure. ABT treatment also decreased urinary sodium, urinary 20-HETE, and renal and microvessel 20-HETE synthesis. This study, to our knowledge, is the first to demonstrate that 20-HETE synthesis in the kidney is altered in time- and site-specific manners during pregnancy. The localized pattern of changes suggests that there are distinct regulatory mechanisms for 20-HETE synthesis in the kidney during pregnancy.
authors.affiliation: Department of Pharmacology, New York Medical College, Valhalla, New York 10595, USA. Mong-Heng_Wang@nymc.edu
authors.forename: Mong-Heng
authors.initials: MH
authors.lastname: Wang
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Zand
authors.forename: Alberto
authors.initials: A
authors.lastname: Nasjletti
authors.forename: Michal
authors.initials: M
authors.lastname: Laniado-Schwartzman
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D042926:Cytochrome P-450 CYP4A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D005260:Female; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis* / Q000652:urine; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D007668:Kidney / Q000098:blood supply / Q000378:metabolism*; D008138:Loop of Henle / Q000378:metabolism; D008833:Microcirculation / Q000502:physiology; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000378:metabolism; D014230:Triazoles / Q000494:pharmacology
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D006893:Hydroxyeicosatetraenoic Acids; D007527:Isoenzymes; D014230:Triazoles; C033020:1-aminobenzotriazole; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid; D003577:Cytochrome P-450 Enzyme System; D012964:Sodium; D006899:Mixed Function Oxygenases; D042926:Cytochrome P-450 CYP4A